This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Gabapentin

Read time: 1 mins
Marketing start date: 23 Dec 2024

Summary of product characteristics


Effective Time

20230926

Version

7

Spl Product Data Elements

Gabapentin Gabapentin GABAPENTIN GABAPENTIN COPOVIDONE K25-31 HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED MAGNESIUM STEARATE MANNITOL POLOXAMER 407 POVIDONE TALC WHITE TO OFF-WHITE OVAL ZE72 Gabapentin Gabapentin GABAPENTIN GABAPENTIN COPOVIDONE K25-31 HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED MAGNESIUM STEARATE MANNITOL POLOXAMER 407 POVIDONE TALC WHITE TO OFF-WHITE OVAL ZE71

Application Number

ANDA078926

Brand Name

Gabapentin

Generic Name

Gabapentin

Product Ndc

65841-706

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 65841-705-01 in bottle of 100 tablets Gabapentin Tablets USP, 600 mg R x only 100 tablets NDC 65841-706-01 in bottle of 100 tablets Gabapentin Tablets USP, 800 mg R x only 100 tablets Gabapentin tablets Gabapentin tablets

Spl Medguide

Manufactured by: Cadila Heathcare Ltd. India

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.